Announcement on Progress of Litigation Involving the Subsidiary
Filed with SSE · · 3 pages · Chinese
Summary by 6ix AI
Shanghai Medicilon, Inc. has announced the progress of litigation involving its subsidiary, Medicilon Puyuan Pharmaceutical Technology (Shanghai) Co., Ltd. The announcement details the basic situation of the lawsuit, including the judgment and withdrawal of counterclaims. The court ruled that the subsidiary must pay a specified amount to the plaintiff, while other claims were dismissed. The company warns that the case may proceed to a second trial, urging investors to be aware of potential risks.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/shanghai-medicilon-incannouncement-on-progress-of-litigation-involving-the-subsidiary
Shanghai Medicilon, Inc. on 6ix
Earlier from Shanghai Medicilon
- Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
- Announcement on Shareholding Reduction Plan of Shareholder
- Announcement on Use of Certain Temporarily Idle Raised Funds for Cash Management
- Indicative Announcement on Shareholders' Equity Change Reaching the 1% Threshold
- Announcement on Subsidiary Filing a Counterclaim
Later from Shanghai Medicilon
- Indicative Announcement on Change in Equity Interests of Shareholder Reaching 1% Threshold
- (688202)"Shanghai Medicilon Inc."Announcement on Progress of Litigation Involving the Subsidiary
- (688202)"Shanghai Medicilon Inc."Announcement on Expiration of Shareholding Reduction Plan of Shareholder and Results of Shareholding Reduction
- (688202)"Shanghai Medicilon Inc."Announcement on Shareholding Reduction Plan of Senior Executive
- (688202)"Shanghai Medicilon Inc."Announcement on Cancellation of Certain Granted but Unvested 2025 Restricted Shares
Follow Shanghai Medicilon into a list and get an email when it puts out news.
Follow Shanghai Medicilon